Imaging Three questions:
Have you've got radiographic studies of the SI joints of all your patients? Have you've got STIR MR sequences of the SI joints of all your patients? The definition of active sacroiliitis depends on the presence of edema of the SpA type in the STIR sequence. The SPARCC and Berlin's score are not used to determine the presence of active sacroiliitis according to ASAS, but to describe the different anomalies of the SI joints Results Please see my comment on SpA groups written above Overall, the text includes a lot of numbers. The reading of such data is difficult. My suggestion is to put most of those numbers and indeed, their intervals on tables or graphs; since some of them are already presented as that, please delete them from the text and ask the reader to check the tables. For me, it is not correct including the involvement of the hips as an extrarticular feature of SpA. Indeed, family history in your study is not what. We would expect. I think you need to re-calculate your numbers according to regrouping your cases (see above). Also, it is very important to get a detailed description of probands and who among their first-degree relatives has any form of SpA. Authors claim that the proportion of SpA among relatives of nrSpA was twice (40%) that of AS (20%) is a major finding in their study. It is, therefore, that authors need to be very clear about the clinical status of probands and first-degree relatives. I don't think that this phenomenon is the result of the association with HLA-B27 nor the exclusion of the clinical arm from the study: 92.5% of 98 AS patients and 83.6% of 117 nrSpA had HLA-B27. I guess, at least 117 with nrSpA patients fulfilled the clinical arm of the ASAS classification. Sex distribution may be relevant as well. Most recent descriptions of SpA populations have reported an increased number of HLA-B27 negative women, some with no response to biologics. Please correct this typo: "AS patients with AS" ... "exhibited…" Discussion Low radiographic sacroiliitis has been also proposed to predict the fulfillment of AS in patients followed up for around five years. Depending on the setting, MR show inflammation in patients with low-grade radiographic changes Regarding family history of SpA in relatives, see my comments above. I don't understand your thought on BASDAI, but the incorporation of subjective perception of the disease in axSpA is correct. We need to important patient's evaluation, in fact, ASDAS is about the same. In contrast, any of the BASMI components, which actually are measures of mobility, are subjected to high inter and intraobserver variability. I agree with author's imitations of the study, but the last one is very important and needs re-approach. In that sense, I would make some important change to "Conclusions" and "Key messages" "Patients who fulfilled only clinical arm of ASAS…" "…these patients were not included I our analysis".
REVIEWER

Answer to comment 1:
Thank you for this comment. Yes, only patients with pure axial or preferentially axial disease were included into our study, some patients had also peripheral involvement, but axial disease was prevailing.
As stated in our text and also title of the manuscript, we have included only patients fulfilling imaging arm into our analysis. We are aware of the missing clinical arm, and have depicted this as a potential limitation of our study -" we excluded nr-axSpA patients fulfilling only the clinical arm of ASAS classification criteria for significantly lower participation in the study and relatively low sensitivity and specificity of the criteria sometimes causing questionable or borderline diagnosis."
Comment 2: Methodology:
Please change two terms, "fleche" and "chin-chest2, to common terms -if they exist-or describe them" regarding the SpA.
Answer to comment 2:
We changed the term "fleche" to "occiput to wall distance" in the text and table 2. The second term "chin-chest distance" is standardized part of ankylosing spondylitis mobility measurement and no other better term exists.
"…metrology (modified Schober, occiput to wall distance, chin-chest distance, chest expansion)…"
Comment 3: Imaging
Three questions:
1. Have you've got radiographic studies of the SI joints of all your patients?
2. Have you've got STIR MR sequences of the SI joints of all your patients?
3. The definition of active sacroiliitis depends on the presence of edema of the SpA type in the STIR sequence. The SPARCC and Berlin's score are not used to determine the presence of active sacroiliitis according to ASAS, but to describe the different anomalies of the SI joints.
Answers to comment 3:
1. Yes, x-ray images of SI joints were performed in all of our patients.
2. No, we were missing 2 STIR MR sequences, however we have detailed description of the MRI examination and there is no doubt these two patients have extended BME fulfilling axSpA criteria.
3. We are familiar that active sacroiliitis depends on presence of BME according to ASSAS. We used SPARCC and Berlin´s score not to determine BME but to measure extension of BME for further biomarker studies planned in the future on these patients, therefore, we have excluded the sentence from the method section -"The modified Berlin and the Spondyloarthritis 
Please correct this typo: "AS patients with AS" ... "exhibited…"
Answers to comment 4.
Thank you for this suggestion. We have reduced the amount of numbers in the text and
address the reader to find exact numbers in enclosed tables as suggested.
Hip arthritis was not included in extraarticular manifestations. It is part of the past history
where peripheral arthritis, hip arthritis and extraarticular manifestations are enumerated.
3. Thank you for this comment. On behalf of your recommendation we did recalculation of the first degree relative's data and we find a mistake in our results. There is no difference in frequency of positive first degree relatives between nr-axSpA and AS subsets (27.1% vs.
22.6%, p=0.460 respectively). Afterwards, we selected only first degree relatives diagnosed with ankylosing spondylitis and no difference was find either (16.4% vs. 13.2%, p=0.590, respectively). Previous results were corrected in the results, discussion and conclusions parts were modified accordingly.
4. We have corrected the text as follows: "AS patients with AS exhibited" was corrected to "AS patients exhibited"
Comment 5: Discussion 1. Low radiographic sacroiliitis has been also proposed to predict the fulfillment of AS in patients followed up for around five years. Depending on the setting, MR show inflammation in patients with low-grade radiographic changes.
2.
Regarding family history of SpA in relatives, see my comments above.
3. I agree with author's limitations of the study, but the last one is very important and needs reapproach. In that sense, I would make some important change to "Conclusions" and "Key messages"
Answers to comment 5
1. We agree with the statement.
2. The comments on family history were implemented to the text. Thank you for this suggestion.
3. Thank you for the comment. Conclusions and key messages were changed as follows:
Conclusions:…In summary, we confirmed that patients with nr-axSpA fulfilling the imaging arm of ASAS classification criteria and patients with AS has mostly the same disease profile, however they differ in gender ratio where woman are more prevalent in nr-axSpA subset.
Surprisingly peripheral arthritis, unlike hip joint involvement, was more prevalent in nr-axSpA subset compared to AS patients in our study. Patients with nr-axSpA and AS exhibited many similarities despite the issue of classification, which suggests a common therapeutic approach.
Key messages:
1. Non-radiographic axSpA (imaging arm) and ankylosing spondylitis have mostly similar disease manifestations.
2. Non-radiographic axSpA is more prevalent in woman than in man contrary to ankylosing spondylitis.
3. Peripheral arthritis was more frequent and hip arthritis less frequent in non-radiographic axSpA compared to ankylosing spondylitis.
4. All axSpA patients should be approached similarly despite of classification ambiguity.
Review 2 Comment 1:
Please state the design of the study with a proper term preferably in title or early in abstract: (I believe this is a cross sectional study).
Answer to comment 1:
Thank you for this comment, we have changed the title as follows:
Cross-sectional study of patients with Axial Spondyloarthritis fulfilling imaging arm of ASAS classification criteria: Baseline Clinical Characteristics and Subset Differences in a Single Centre
Cohort
Comment 2:
Were there a predefined protocol for the study, and if so where can it be found. Please clarify.
Answer to comment 2:
Predefined protocol of the study was not published. It was written for persons conducting the study and authorized by local ethics committee of the Institute of Rheumatology in Prague. Protocol can be translated and sent in case of interest.
Comment 3:
Being a cross sectional study of consecutive patients risk of bias surely exist and should be addressed, discussed and compensated as possible.
Answer to comment 3:
Thank you for the comment. We included the statement to the end of the discussion part: …We have tried to reduce possible bias by excluding patients fulfilling only the clinical arm of ASAS classification criteria and work only with patients with sacroiliitis confirmed by MR (nr-axSpA) and conventional x-ray (AS). Clinical arm of ASAS patients has relatively good sensitivity however specificity is low and our intention was to eliminate the false positive patients as much as possible…
Comment 4:
Please describe confounding by indication in terms of treatment: ie. Mild disease receiving only NSAID. In general all statements about potential causality should be omitted.
Answer to comment 4:
Thank you for the comment. We agree and included the text about the treatment in patients and methods section as follows: ... "Both axSpA subsets were treated according to the EULAR recommendations for the management of spondyloarthritis. Patients with mild disease were treated with NSAIDs on demand. Most of the patients with previously developed peripheral arthritis were treated with csDMARDs. Patients with severe disease were treated with bDMARDs."… There was no significant difference between the treatment of nr-axSpA patients and AS patients as is stated in the table 1.
Comment 5:
Patient and Public Involvement:
Authors must include a statement in the METHOD section of the manuscript under the sub-heading This should provide a brief response to the following questions:
How was the development of the research question and outcome measures informed by patients' priorities, experience, and preferences?
How did you involve patients in the design of this study?
Were patients involved in the recruitment to and conduct of the study?
How will the results be disseminated to study participants?
For randomised controlled trials, was the burden of the intervention assessed by patients themselves?
Patient advisers should also be thanked in the contributorship statement/acknowledgements.
If patients and or public were not involved please state this.
Answers to comment 5:
Thank you for the comment. The Patient and Public Involvement was included in the Method section.
The Patient and Public Involvement:
The patients and/or public were not involved in the design, recruitment or conduct of the study.
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